No Data
Unnamed Pharmaceuticals: Report for the first quarter of 2025
Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Adding insult to injury! The core subsidiary of Shandong Sinobioway Biomedicine has been halted from production, with a revenue share of 60% | Quick read announcement.
① A subsidiary of Shandong Sinobioway Biomedicine responsible for the production and sale of interferon products has been subjected to risk control measures that involve the suspension of production and sales due to failing the Pharmaceutical GMP compliance inspection. ② Previously, Shandong Sinobioway Biomedicine's interferon α2b spray was recalled from shelves due to inspection results indicating that its "biological activity does not meet regulations."
Shandong Sinobioway Biomedicine: Summary of the 2024 Annual Report
Shandong Sinobioway Biomedicine: 2024 Annual Report
Shandong Sinobioway Biomedicine (SZSE:002581 Investor Three-year Losses Grow to 46% as the Stock Sheds CN¥369m This Past Week
Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
